...
首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >A comparison of hormonal profiles between breast cancer and benign breast disease: A case-control study
【24h】

A comparison of hormonal profiles between breast cancer and benign breast disease: A case-control study

机译:乳腺癌与良性乳腺疾病荷尔蒙谱的比较:案例对照研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Benign breast disease (BBD), particularly proliferative BBD, is an established breast cancer risk factor. However, there has been no systematic attempt to compare the hormonal profiles of the two conditions. In a case-control investigation in Athens, Greece, we compared levels of estrogens, testosterone and insulin-like growth factor-1 (IGF-1), as well as their principal binding proteins, between breast cancer patients, women with BBD by histological type (proliferative and nonproliferative) and women with no breast pathology. Patients and methods: We studied 466 women with incident breast cancer, 704 women with BBD and 244 healthy women. We used multiple regression to compare log-transformed serum hormone levels of breast cancer patients with those of healthy women and women with BBD by histological type (proliferative and nonproliferative BBD). Results: The hormonal profile of breast cancer in our study was in line with the generally accepted hormonal profile of this disease, as reported from large cohort studies. Compared with healthy women, breast cancer patients tended to have higher levels of steroid hormones. The evidence was strong for estrone (difference 21.5%, P < 0.001), weaker for testosterone (difference 15.8%, P = 0.07) and weaker still for estradiol (difference 12.0%, P = 0.18). Also compared with healthy women, breast cancer patients had barely higher levels of IGF-1 (difference 2.0%, P = 0.51), but had significantly lower levels of IGF binding protein 3 (IGFBP-3) (difference -6.7%, P = 0.001). Compared with women with BBD, breast cancer patients had nonstatistically significantly lower levels of steroid hormones, but they had higher levels of IGF-1 [difference 5.5%, 95% confidence interval (CI) 0.7% to 10.6%] and lower levels of IGFBP-3 (difference -3.7%, 95% CI -6.7% to -0.7%). Differences were more pronounced when breast cancer patients were contrasted to women with proliferative BBD. Conclusions: Our findings suggest that high levels of IGF-1 may be an important factor toward the evolution of BBD to breast cancer.
机译:背景:良性乳腺疾病(BBD),特别是增殖性BBD,是一种已建立的乳腺癌危险因素。然而,没有系统尝试比较两个条件的激素谱。在希腊雅典的病例调查中,我们将雌激素,睾酮和胰岛素样生长因子-1(IGF-1)的水平进行比较,以及它们在乳腺癌患者之间的主要结合蛋白质,通过组织学患有BBD的女性类型(增殖性和非促进剂)和没有乳房病理学的妇女。患者和方法:我们研究了466名患有事件乳腺癌的女性,704名妇女BBD和244名健康女性。我们使用多元回归来将乳腺癌患者的血清血清激素水平与组织学型(增殖和非促进BBD)进行了健康妇女和女性的乳腺癌患者的乳腺癌患者。结果:我们研究中乳腺癌的荷尔蒙曲线符合本病的普遍接受的荷尔蒙曲线,如大型队列研究所报告。与健康女性相比,乳腺癌患者往往具有更高水平的类固醇激素。睾酮的证据强劲(差异21.5%,P <0.001),睾酮较弱(差异15.8%,P = 0.07),雌二醇仍然较弱(差异12.0%,P = 0.18)。还与健康女性相比,乳腺癌患者的IGF-1水平几乎较高(差异2.0%,P = 0.51),但IGF结合蛋白3的水平显着降低(IGFBP-3)(差异-6.7%,P = 0.001)。与BBD的女性相比,乳腺癌患者的类固醇激素水平较低,但它们具有更高的IGF-1水平[差异5.5%,95%置信区间(CI)0.7%至10.6%]和IGFBP水平较低-3(差异-3.7%,95%CI -6.7%至-0.7%)。当乳腺癌患者与具有增殖BBD的女性形成鲜明对比时,差异更加明显。结论:我们的研究结果表明,高水平的IGF-1可能是BBD对乳腺癌进化的重要因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号